Today Pharming announces that two abstracts were presented at The Western Society of Allergy, Asthma and Immunology (WSAAI) in Maui, Hawaii, USA on January 22-24, 2019.
Today Pharming acknowledged presentation of the results from an investigator-initiated comparative study of therapies in acute attacks of hereditary angioedema (“HAE”).
Pharming presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2018.
Today Pharming announced positive results from a Phase II investigator-initiated study of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) in a double-blind, placebo-controlled clinical trial in patients at risk of nephropathy resulting from contrast-enhanced examinations.
Today Pharming announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the supplemental Biologics License Application (sBLA) for RUCONEST® [C1 Esterase Inhibitor (recombinant)] to expand the current indication to include prophylaxis in patients with hereditary angioedema (HAE).
Today Pharming announced that it has issued a total of 6,240,000 new shares following exercise of warrants representing a total of 6,240,000 shares.
Pharming presents its (unaudited) financial report for the six months ended 30 June 2018.
Pharming announces the agenda for its Capital Markets Briefing to be held from 08:00 to 10:30 EST/14:00-16:30 CET on 21 June 2018 in New York, NY, and through a live webcast.
Pharming announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.
Pharming presents its (unaudited) financial report for the quarter ended 31 March 2018.
